Medicus Pharma Ltd. Announces First Patient Randomized in Phase 2 Trial of SKNJCT-003 for the Treatment of Nodular Basal Cell Carcinoma in Adults© Invezz Corporate Logo© Invezz ...

On August 27, 2024, Medicus Pharma (TSXV:MDCX) announced that the first patient (of up to 60 subjects) has been randomized in the Phase 2 clinical trial (SKNJCT-003) for the treatment of nodular ...

Champion discussed treatment he sought for an unusual mark on his face, which turned out to be nodular basal cell carcinoma, on “Good Morning America” Friday. “We started talking about it ...

A randomized, double blind, placebo-controlled, multicenter study, SKNJCT-003 will enroll up to 60 patients with nodular basal cell carcinoma (BCC) in the U.S. Patients will be randomly assigned ...

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) Provided by GlobeNewswire Feb 14, 2025 12:30pm ...

TOPLINE: In a randomized trial, recurrence was higher after superficial curettage (SC) plus imiquimod cream than surgical excision (SE) in patients with nodular basal cell carcinoma (nBCC ...

Superficial curettage plus imiquimod cream 5% in the treatment of nodular basal cell carcinoma showed more treatment failure at 5 years vs. surgical excision, according to a study.“Surgical ...

News for Medicus Pharma Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) ...

The weatherman had nodular basal cell carcinoma in his cheek. X / @SamChampion ... Champion, 63, noted that he also underwent laser treatment to remove dark, precancerous dots elsewhere on his face.

'Good Morning America' weatherman Sam Champion announced on the show that he recently had a new bout of skin cancer after doctors found an "unusual" mark on his face.